Each enrolled patient will be assessed by the trained research nurse utilising the compilation of data collection tools – this will allow for a comparison of data collected by the research nurse, who will complete chart reviews, and the site nurses, thus allowing an evaluation of the reliability of QI information obtained by chart audit (through triangulation of data). The patient will Inhibitors,research,lifescience,medical otherwise undergo usual ED assessment and selleck compound management. Two research staff, with

nursing backgrounds will be trained to complete the site visits. One site visit will be completed jointly, but scored separately to test the data collection tool with respect to inter-rater reliability. All remaining site visits will be visited by one of the two research staff. Research nursing staff will be trained

to complete the chart review. The data will be Inhibitors,research,lifescience,medical collected in a retrospective fashion by trained chart/database abstractors using a standardized chart abstraction protocol – these abstractors will be blinded to the site nurse assessment. The training will include the protocol, supervised practice charts and independent chart review followed by comparison with trainer review. 5% of charts will be co-reviewed to ensure a kappa of>0.7, which by convention selleck chemicals MG132 suggests excellent inter-rater reliability [58]. Staff carrying out the data collection will be blinded to the individual QIs. Inhibitors,research,lifescience,medical All data items, Inhibitors,research,lifescience,medical regardless of the data collection method (prospective, chart review, site visit) will be standalone items and not be grouped or identified in the data collection sheet as linked to an individual QI. Data collection The research nurse at each site will identify eligible patients at the beginning of each shift using the EDIS. All eligible patients will be approached in consecutive order. If a patient becomes ineligible or is excluded, general demographic information will be recorded, along with the reason for

ineligibility. For eligible patients, the research nurse will explain the purpose Inhibitors,research,lifescience,medical of the study, the range of questions that will be asked and the anticipated duration of the patient’s involvement and seek written consent from the patient or a nominated secondary decision maker for participation. The research nurse will confirm general contact and demographic information with the patient. The initial data collection questions will focus on Carfilzomib the patient’s current condition or situation, and include items relating to cognition, delirium, pain, medications, skin integrity and continence (these questions relate to aspects of health that may change before and during the ED episode). A second series of questions will be related to the patient’s situation prior to the onset of the acute medical condition, the reason for attending the ED, and arrangements for additional care following the ED episode (capacity to get home, additional nursing care, etc.).